Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

St. Jude sues Volcano Corp.

This article was originally published in The Gray Sheet

Executive Summary

St. Jude Medical alleges that several products developed by Volcano, including its PrimeWire pressure guide wire products, infringe on five patents used for St. Jude's PressureWire technology platform, which was acquired from Radi Medical Systems in December 2008 (1"The Gray Sheet" Jan. 5, 2009). Two other St. Jude Medical affiliates are also plaintiffs, according to the firm. The suit, which St. Jude announced on July 27, is filed in the U.S. District Court for the District of Delaware and seeks injunctive relief and monetary damages

You may also be interested in...



Holiday Shopping: St. Jude Adds To A-Fib, Cardio Units With Two Acquisitions

St. Jude Medical acquired two privately-held firms just before the New Year for a total of $550 million, gaining tools for artery lesion assessment and precise interventional procedure navigation, among other technologies

UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026

Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029209

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel